Syntara Names CFO Tim Luscombe as New Company Secretary

An update from Syntara Limited ( (AU:SNT) ) is now available.

Syntara Limited has appointed its existing Chief Financial Officer, Tim Luscombe, as Company Secretary, effective immediately, making him the primary contact for the company’s ASX listing rule matters. Former Company Secretary Cameron Billingsley has resigned from that role but will continue to support Syntara as external general counsel, a move that consolidates corporate governance responsibilities while retaining legal continuity as the biotech advances its portfolio of clinical-stage drug candidates in oncology, fibrosis, and inflammatory disease.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.

More about Syntara Limited

Syntara Limited (ASX: SNT) is a Sydney-based clinical-stage drug development company focused on targeting extracellular matrix dysfunction, leveraging expertise in amine oxidase chemistry to develop novel medicines for blood cancers and diseases linked to inflammation and fibrosis. Its lead candidate, amsulostat (SNT-5505), is being developed for myelofibrosis and myelodysplastic syndromes, supported by FDA Fast Track and Orphan Drug Designations, while additional programs include topical pan-LOX inhibitors for hypertrophic and keloid scars, an SSAO/MAO-B inhibitor for neuroinflammatory conditions such as Parkinson’s-related sleep disorders, and a broader pipeline addressing kidney, liver (MASH), pulmonary and cardiac fibrosis; the company previously commercialised and sold two respiratory products, Bronchitol and Aridol, in 2023.

Average Trading Volume: 1,456,553

Technical Sentiment Signal: Sell

Current Market Cap: A$50.6M

For an in-depth examination of SNT stock, go to TipRanks’ Overview page.